Dosing in neonates: special considerations in physiology and trial design
暂无分享,去创建一个
[1] P. Smith,et al. Higher clearance of micafungin in neonates compared with adults: role of age‐dependent micafungin serum binding , 2011, Biopharmaceutics & drug disposition.
[2] A H Neims,et al. Pharmacokinetic aspects of theophylline in premature newborns. , 1976, The New England journal of medicine.
[3] B. Poindexter,et al. Population Pharmacokinetics of Meropenem in Plasma and Cerebrospinal Fluid of Infants With Suspected or Complicated Intra-abdominal Infections , 2011, The Pediatric infectious disease journal.
[4] G. Koren. Therapeutic drug monitoring principles in the neonate. National Academy of CLinical Biochemistry. , 1997, Clinical chemistry.
[5] M. Rasmussen,et al. Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the Neonate , 2008, The Pediatric infectious disease journal.
[6] K. Allegaert,et al. Neonatal pharmacology: extensive interindividual variability despite limited size. , 2011, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.
[7] H. Pandya,et al. Dexamethasone quantification in dried blood spot samples using LC-MS: The potential for application to neonatal pharmacokinetic studies. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[8] S. Howie,et al. Blood sample volumes in child health research: review of safe limits. , 2011, Bulletin of the World Health Organization.
[9] M. Kuo,et al. Postnatal development of organic cation transport and mdr gene expression in mouse kidney. , 1992, The Journal of pharmacology and experimental therapeutics.
[10] B. Poindexter,et al. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Ronald N Hines,et al. The ontogeny of drug metabolism enzymes and implications for adverse drug events. , 2008, Pharmacology & therapeutics.
[12] J. Ramasethu. Complications of vascular catheters in the neonatal intensive care unit. , 2008, Clinics in perinatology.
[13] M. Laughon,et al. Drug labeling and exposure in neonates. , 2014, JAMA pediatrics.
[14] K. Markarian,et al. Phases of fluid and electrolyte homeostasis in the extremely low birth weight infant. , 1995, Pediatrics.
[15] E. Kimland,et al. Off‐Label Drug Use in Pediatric Patients , 2012, Clinical pharmacology and therapeutics.
[16] D. Notterman,et al. Alternative routes of drug administration - Advantages and disadvantages (subject review) , 1997 .
[17] G. Kearns,et al. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. , 2000, The Journal of allergy and clinical immunology.
[18] A. Warner. Drug use in the neonate: interrelationships of pharmacokinetics, toxicity, and biochemical maturity. , 1986, Clinical chemistry.
[19] A. Smits,et al. Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. , 2013, International journal of pharmaceutics.
[20] W. Zempsky. Alternative Routes of Drug Administration— Advantages and Disadvantages (Subject Review) , 1998, Pediatrics.
[21] M. Walsh,et al. Population Pharmacokinetics of Metronidazole Evaluated Using Scavenged Samples from Preterm Infants , 2012, Antimicrobial Agents and Chemotherapy.
[22] G. Kearns,et al. Effect of Diet on the Development of Drug Metabolism by Cytochrome P-450 Enzymes in Healthy Infants , 2006, Pediatric Research.
[23] J. N. van den Anker,et al. DEVELOPMENTAL PHARMACOLOGY: NEONATES ARE NOT JUST SMALL ADULTS… , 2008, Acta clinica Belgica.
[24] K. Oselin,et al. Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight Neonates , 2012, Antimicrobial Agents and Chemotherapy.
[25] A. Langslet. NEONATAL PHARMACOLOGY , 1974, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[26] J. McElnay,et al. Metronidazole Population Pharmacokinetics in Preterm Neonates Using Dried Blood-Spot Sampling , 2011, Pediatrics.
[27] P. Smith,et al. Determining Population and Developmental Pharmacokinetics of Metronidazole Using Plasma and Dried Blood Spot Samples From Premature Infants , 2013, The Pediatric infectious disease journal.
[28] R. Kauffman,et al. Basics and dynamics of neonatal and pediatric pharmacology. , 2011, Handbook of experimental pharmacology.
[29] F. Sorgel,et al. Meropenem Pharmacokinetics in the Newborn , 2009, Antimicrobial Agents and Chemotherapy.
[30] P. Routledge. Pharmacokinetics in children. , 1994, The Journal of antimicrobial chemotherapy.
[31] P. Smith,et al. Fluconazole Loading Dose Pharmacokinetics and Safety in Infants , 2011, The Pediatric infectious disease journal.
[32] H. Mulla. Understanding Developmental Pharmacodynamics , 2010, Paediatric drugs.
[33] H. Pandya,et al. Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. , 2013, British journal of clinical pharmacology.
[34] Susan M Abdel-Rahman,et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.
[35] F. Guillemin,et al. Glomerular Filtration Rate Reference Values in Very Preterm Infants , 2010, Pediatrics.
[36] D. Kaufman,et al. Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates , 2009, The Pediatric infectious disease journal.
[37] G. Kearns,et al. Developmental pharmacokinetics. , 2011, Handbook of experimental pharmacology.
[38] V. Narendran,et al. The Ontogeny of Skin. , 2014, Advances in wound care.
[39] N. Saunders,et al. Barriers in the developing brain and Neurotoxicology. , 2012, Neurotoxicology.
[40] P. Smith,et al. Population Pharmacokinetics of Micafungin in Neonates and Young Infants , 2010, Antimicrobial Agents and Chemotherapy.
[41] P. Annaert,et al. The ontogeny of drug metabolizing enzymes and transporters in the rat. , 2008, Reproductive toxicology.
[42] D. Tibboel,et al. Ontogeny of Human Hepatic and Intestinal Transporter Gene Expression during Childhood: Age Matters , 2014, Drug Metabolism and Disposition.
[43] K. Brouwer,et al. Pharmacokinetics and Safety of Fluconazole in Young Infants Supported With Extracorporeal Membrane Oxygenation , 2012, The Pediatric infectious disease journal.
[44] M. Laughon,et al. Innovative clinical trial design for pediatric therapeutics , 2011, Expert review of clinical pharmacology.
[45] O. Della Pasqua,et al. Development of paediatric medicines: concepts and principles. , 2011, Handbook of experimental pharmacology.
[46] A. Zajicek. The National Institutes of Health and the Best Pharmaceuticals for Children Act , 2009, Paediatric drugs.
[47] M. J. Bell,et al. Pharmacokinetics of clindamycin phosphate in the first year of life. , 1984, The Journal of pediatrics.
[48] G. Kearns,et al. The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants , 2006, The Pediatric infectious disease journal.
[49] M. Walsh,et al. Population Pharmacokinetics of Piperacillin Using Scavenged Samples From Preterm Infants , 2012, Therapeutic drug monitoring.
[50] C. Ross,et al. Gentamicin and verapamil compete for a common transport mechanism in renal brush border membrane vesicles. , 1989, The Journal of pharmacology and experimental therapeutics.
[51] B. Ali,et al. Gentamicin nephrotoxicity in humans and animals: some recent research. , 1995, General pharmacology.
[52] G. Koren,et al. Clinical pharmacology and therapeutic drug monitoring in neonates and children. , 1998, Pediatrics in review.
[53] M. Brodie,et al. Enzyme induction with antiepileptic drugs: Cause for concern? , 2013, Epilepsia.
[54] B. Anderson. Pharmacology in the very young: anaesthetic implications , 2012, European journal of anaesthesiology.
[55] H. Lafeber,et al. Pharmacokinetics of Meropenem in Preterm Neonates , 2001, Therapeutic drug monitoring.
[56] Bill J Smith,et al. Progress in Brain Penetration Evaluation in Drug Discovery and Development , 2008, Journal of Pharmacology and Experimental Therapeutics.
[57] D. G. McCarver,et al. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. , 2002, The Journal of pharmacology and experimental therapeutics.
[58] K. Watterberg. Evidence-based neonatal pharmacotherapy: postnatal corticosteroids. , 2012, Clinics in perinatology.
[59] C. Yokoyama,et al. Developmental Changes in P-Glycoprotein Function in the Blood–Brain Barrier of Nonhuman Primates: PET Study with R-11C-Verapamil and 11C-Oseltamivir , 2011, The Journal of Nuclear Medicine.
[60] S. Jadcherla,et al. Effect of Erythromycin on Gastroduodenal Contractile Activity in Developing Neonates , 2002, Journal of pediatric gastroenterology and nutrition.
[61] D. Kaufman,et al. Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants , 2009, The Pediatric infectious disease journal.
[62] D. Azzopardi,et al. Elevated Morphine Concentrations in Neonates Treated With Morphine and Prolonged Hypothermia for Hypoxic Ischemic Encephalopathy , 2008, Pediatrics.
[63] R. Hines. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. , 2013, International journal of pharmaceutics.
[64] G. Kearns,et al. Ontogeny of drug metabolizing enzymes in the neonate. , 2005, Seminars in fetal & neonatal medicine.
[65] Catherine Tom-Revzon. Erratic absorption of intramuscular antimicrobial delivery in infants and children , 2007, Expert opinion on drug metabolism & toxicology.
[66] G. Koren. Therapeutic drug monitoring principles in the neonate , 1997 .
[67] M. Laughon,et al. Fluconazole pharmacokinetics and safety in premature infants. , 2012, Current medicinal chemistry.
[68] D. Benjamin,et al. Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes , 2008, Drug Metabolism and Disposition.
[69] D. Kaufman,et al. Safety and Pharmacokinetics of Repeat‐Dose Micafungin in Young Infants , 2010, Clinical pharmacology and therapeutics.
[70] Yi Wang,et al. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants , 2013, European Journal of Clinical Pharmacology.
[71] R. Mcdonald,et al. Antibiotic sampling from central venous catheters versus peripheral veins. , 2004, Pediatric nursing.
[72] B. Poindexter,et al. Developmental Pharmacokinetics of Piperacillin and Tazobactam Using Plasma and Dried Blood Spots from Infants , 2014, Antimicrobial Agents and Chemotherapy.
[73] J. Ghersi-Egea,et al. Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. , 2013, Molecular pharmaceutics.
[74] D. Kaufman,et al. Population Pharmacokinetics of Fluconazole in Young Infants , 2008, Antimicrobial Agents and Chemotherapy.
[75] P. Smith,et al. Pharmacokinetics and Tolerability of Single-Dose Daptomycin in Young Infants , 2012, The Pediatric infectious disease journal.